Zimmer Biomet Holdings, Inc. filings document a public medical technology company with common stock listed under ZBH and several registered notes listed on the New York Stock Exchange. Recent 8-K reports cover quarterly and annual operating results, updated financial guidance, executive officer departures and interim finance leadership, debt securities, and completed acquisition activity.
The company's proxy and event filings disclose board and executive compensation matters, governance votes, Section 12(b) securities, material agreements, senior unsecured debt obligations, and exhibits tied to earnings releases. These records frame Zimmer Biomet's capital structure, leadership changes, shareholder governance and financial reporting for its orthopedic and musculoskeletal technology business.
Zimmer Biomet Holdings reported second quarter 2026 results with net sales of $2.177 billion, up 4.8% year over year, including 4.7% growth on a constant-currency basis and 4.0% on an organic constant-currency basis. GAAP net earnings were $198.3 million and diluted EPS was $1.03, a 33.8% increase. Adjusted net earnings were $399.6 million and adjusted diluted EPS was $2.07. Operating cash flow reached $447.9 million and free cash flow was $308.3 million in the quarter.
Growth was balanced across geographies, with United States sales up 5.6% and international sales up 3.7%. By product category, Knees were roughly flat, Hips grew 5.0%, S.E.T. grew 6.4%, and Technology & Data, Bone Cement and Surgical grew 21.1% on a reported basis. For full‑year 2026, the company raised its outlook, now expecting reported revenue growth of 3.9%–4.9%, organic constant‑currency growth of 2.25%–3.25%, and adjusted diluted EPS of $8.47–$8.59. Zimmer Biomet also increased share repurchase expectations to up to $1 billion of common stock in fiscal 2026.
ZIMMER BIOMET HOLDINGS executive Kevin R. Thornal exercised 9,957 Restricted Stock Units into 9,957 shares of common stock on August 1, 2026. To satisfy tax obligations on this RSU vesting, 4,266 shares were withheld at $92.68 per share. Following the transaction, Thornal held 19,913 RSUs, with the remaining units scheduled to vest half on August 1, 2027 and half on August 1, 2028.
Zimmer Biomet Holdings, Inc. executive Desai Chintan, serving as President, APAC, filed an initial Form 3 as a reporting person. The report lists no stock transactions, holdings entries, or derivative positions for Zimmer Biomet securities in the structured data provided.
ZBH shareholder Suketu Upadhyay submitted a Form 144 notice for a proposed sale of up to 7,668 shares of common stock through Fidelity Brokerage Services LLC. These shares have an aggregate market value of $712,050.48, when 193,462,482 common shares were outstanding, and are expected to be sold on or about July 16, 2026 on the NYSE.
The securities to be sold were acquired through restricted stock vesting as compensation on July 1, 2021 (2,543 shares), February 25, 2024 (2,483 shares), and March 6, 2024 (2,642 shares). Upadhyay also completed sales in the prior three months of 31,252 shares for $2,608,859.38 on May 12, 2026, 5,372 shares for $464,120.14 on May 19, 2026, and 4,560 shares for $410,696.40 on June 24, 2026.
Hilado Maria Teresa reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Maria Teresa Hilado received a grant of 389.498 Phantom Stock Units. These units track the value of Zimmer Biomet common stock on a 1-for-1 basis but are settled in cash, not shares.
The units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors. Following this award, Hilado now holds a total of 12,983.867 Phantom Stock Units. Settlement is scheduled in ten annual cash installments after her service as a director ends.
Zimmer Biomet Holdings director Devdatt Kurdikar received a grant of phantom stock units as part of board compensation. On the reported date, he acquired 180.323 phantom stock units under the company’s Deferred Compensation Plan for Non-Employee Directors, increasing his balance to 2,990.182 units.
Each phantom stock unit is linked 1-for-1 to a share of Zimmer Biomet common stock and is scheduled to be settled in company shares within sixty days after his service as a director ends.
HAGEMANN ROBERT reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Robert Hagemann received a grant of 317.369 Phantom Stock Units, equivalent on a 1-for-1 basis to shares of common stock. These units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors and are settled only in cash.
After this award, Hagemann holds a total of 33,269.443 Phantom Stock Units. The units will be paid out in five annual cash installments that begin within sixty days after the calendar year in which his service as a director ends, linking this compensation to his board tenure rather than near-term market trading.
HIGGINS ARTHUR J reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Arthur J. Higgins received a grant of 317.369 Phantom Stock Units under the company’s Deferred Compensation Plan for Non-Employee Directors. Each unit is linked 1-for-1 to a share of common stock but will be settled in cash, not stock.
After this award, Higgins holds a total of 37,674.691 Phantom Stock Units on a direct basis. These units are scheduled to be paid out in cash in ten annual installments, beginning within sixty days after the end of the calendar year in which his service as a director ends.
Kolli Sreelakshmi reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings, Inc. director Sreelakshmi Kolli received a grant of 180.323 phantom stock units as a compensation award under the company’s deferred compensation plan for non-employee directors. Following this grant, she holds a total of 6,842.604 phantom stock units, which will be settled in common stock within sixty days after her board service ends.
Farrell Michael J. reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Michael J. Farrell received a grant of 432.776 phantom stock units on June 30, 2026. These units are credited under the company’s Deferred Compensation Plan for Non-Employee Directors at a 1-for-1 rate with common stock and are to be settled in cash after his board service ends. Following this award, Farrell holds a total of 19,606.716 phantom stock units, reflecting routine, cash-settled director compensation rather than any open-market trading.